Every Form 4 that Guardant Health, Inc. (GH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On March 17, 2026, 232 restricted stock units converted into 232 shares of common stock at a stated price of $0.00 per share, raising his direct common stock holdings to 1,425 shares. The award originated from a grant on July 17, 2024 that vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly over the following three years.
Guardant Health Co-CEO AmirAli Talasaz reported compensation-related equity activity and trust-related share movements. On March 17, 2026, he received awards of 11,268 and 101,409 restricted stock units that vest over quarterly and multi-year schedules. Earlier, on January 1 and March 13, 2026, performance-based and time-based RSUs covering 38,283 and 26,961 shares were exercised into common stock, with 19,402 and 13,664 shares withheld by the company to cover tax obligations. In connection with these events, 13,209 common shares were transferred from direct ownership into the Talasaz and Eskandari 2017 Family Trust, which held 2,128,489 shares after the March 13, 2026 transactions.
Guardant Health Co-CEO Helmy Eltoukhy reported compensation-related equity activity and trust transfers, not open‑market trading. On March 17, 2026, he received two new restricted stock unit awards covering 11,268 and 101,409 shares of common stock, with multi-year vesting schedules.
On January 1, 2026 and March 13, 2026, performance-based and time-based RSUs were exercised into a total of 65,244 shares of common stock. In connection with these vestings, the company withheld 19,402 and 13,664 shares to cover tax obligations, which were not market sales.
The filing also records a transfer of 13,209 shares from direct ownership to the Helmy A. Eltoukhy Revocable Trust, after which the trust held 2,094,904 shares. Overall, the transactions increase his equity-based compensation and shift holdings into a revocable trust while maintaining a substantial indirect position.
Guardant Health director Tariq Musa exercised restricted stock units into common shares as part of a scheduled vesting. On March 15, 2026, 249 restricted stock units converted into 249 shares of common stock at a stated price of $0.0000 per share.
Following the transactions, he held 8,742 shares of common stock directly and 2,999 restricted stock units. The underlying restricted stock unit award was granted on March 6, 2023 and vests over four years, with 25% vesting on the one-year anniversary of March 15, 2023 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity awards vesting and converting into common stock on March 15, 2026. Performance-based and time-based restricted stock units were exercised under code “M,” delivering additional Guardant Health common shares.
The company retained 4,622 shares at $85.49 per share under code “F” to satisfy Mr. Saia’s tax withholding obligations, as described in the footnotes. After these transactions, he directly owns 56,903 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Information Officer Kumud Kalia exercised equity awards that vested on March 15, 2026. A performance-based restricted stock unit award converted into 12,856 shares of common stock, and a separate restricted stock unit award converted into 637 shares of common stock, both at a price of $0.00 per share.
The company withheld 6,839 shares of common stock at $85.49 per share to satisfy tax obligations related to the vesting, which is treated as a tax-withholding disposition rather than an open-market sale. After these transactions, Kalia directly held 44,297 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman exercised performance-based and time-based restricted stock units into common stock. On March 15, 2026, 15,426 performance-based RSUs and 1,402 RSUs converted into an equal number of common shares at a conversion price of $0.00 per share. To cover tax withholding obligations on this vesting, 7,127 common shares were retained by the company at $85.49 per share, as a tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly holds 53,571 shares of Guardant Health common stock. The performance-based award was granted on June 7, 2023 with a three-year performance metric, and the RSU award was granted on June 9, 2023 with vesting over three years.
Guardant Health Chief Medical Officer Craig Eagle exercised and vested stock awards, with part withheld for taxes. On March 15, 2026, performance-based and time-based restricted stock units covering 13,712 and 1,402 shares of common stock, respectively, were converted into common shares at no exercise price. The company retained 7,661 shares of common stock at $85.49 per share to satisfy Dr. Eagle’s tax withholding obligations related to this vesting, rather than selling shares on the open market. Following these transactions, Dr. Eagle directly holds 66,380 shares of Guardant Health common stock. No remaining derivative awards related to these units are shown after this filing.
Guardant Health Chief Technology Officer Darya Chudova exercised performance-based equity and had shares withheld for taxes. On March 15, 2026, a performance-based restricted stock unit award covering 10,714 units converted into 10,714 shares of common stock after the second performance tranche was achieved.
The company then withheld 5,759 of those common shares, valued at $85.49 per share, to cover tax obligations associated with the vesting, as disclosed in the footnotes. After these transactions, Chudova directly held 64,352 shares of Guardant Health common stock, reflecting a routine compensation-related equity increase rather than an open-market trade.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions. On March 15, 2026, restricted stock units and performance-based restricted stock units covering a total of 13,790 shares of Common Stock vested and were converted at a $0.0000 exercise price. To satisfy tax obligations on this vesting, 7,413 shares were withheld by the company at a price of $85.4900 per share. On March 16, 2026, Bell completed an open-market sale of 3,000 shares of Common Stock at a weighted average price of $87.0370 per share. After these transactions, he directly holds 43,601 shares of Guardant Health Common Stock.
Guardant Health, Inc. reported that Chief Legal Officer John G. Saia received a grant of 20,448 restricted stock units tied to Guardant Health common stock. These RSUs were awarded on March 11, 2026 as part of his equity compensation and do not involve any cash share purchases or sales.
According to the vesting schedule, 33% of the RSUs will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Saia directly holds 20,448 RSUs, which will convert into common shares only as they vest.
Monroe Terilyn J. reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief People Officer Terilyn J. Monroe received a grant of 17,040 Restricted Stock Units on March 11, 2026. These RSUs represent the right to receive an equal number of Guardant common shares as they vest over time.
According to the award terms, 33% of the RSUs will vest on April 1, 2027, and the remaining 67% will vest in equal quarterly installments over the following two years. After this grant, Monroe holds 17,040 RSUs directly, reflecting a routine equity compensation award rather than an open‑market purchase or sale.
Kalia Kumud reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Information Officer Kalia Kumud received a grant of 13,632 restricted stock units (RSUs) on March 11, 2026. The award vests over three years: 33% on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Kumud holds 13,632 RSUs directly.
Freeman Chris reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Commercial Officer Chris Freeman received a grant of 18,744 restricted stock units. These RSUs, which represent rights to receive an equal number of common shares, were awarded as compensation and involve no cash purchase or market trade.
The award granted on March 11, 2026 vests over three years: 33% of the units vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Freeman holds 18,744 RSUs directly.
Guardant Health, Inc. Chief Technology Officer Darya Chudova reported a grant of 23,856 restricted stock units. The award was granted on March 11, 2026 and will convert into an equal number of common shares as it vests. According to the vesting schedule, 33% of the units will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, her reported direct holdings in this award total 23,856 restricted stock units.
Bell Michael Brian reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell received a grant of 26,582 restricted stock units on March 11, 2026 as equity compensation. The award vests over three years: 33% on April 1, 2027 and the remaining 67% in equal quarterly installments over the following two years, settling in common stock as units vest.
Guardant Health, Inc. director Manuel Hidalgo Medina reported option exercises and share sales in company stock. On March 6, 2026, he exercised a stock option for 1,000 shares at a price of $0.00 per share, receiving 1,000 shares of common stock valued at $32.55 per share in the transaction record.
The same day, he sold a total of 1,300 shares of common stock in open-market transactions at average prices of $91.6065 and $91.3001 per share, leaving him with 1,193 common shares held directly after the sales. The underlying stock option was originally granted on July 17, 2024 and vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
Guardant Health Chief Information Officer Kumud Kalia exercised stock options and sold shares on March 4, 2026. He exercised multiple stock option awards, converting them into common stock at exercise prices including $47.20, $74.00, $32.86, $28.37, and $28.61 per share.
On the same date, he sold a total of 40,000 shares of Guardant Health common stock in open-market transactions at weighted average prices of about $95.12 and $95.73 per share, across ranges disclosed in the footnotes. After these trades, he directly held 37,643 shares of common stock.
The option awards he exercised were originally granted between April 20, 2020 and November 8, 2024 and vest over three- or four-year schedules, with initial portions vesting on specified dates and remaining shares vesting in equal monthly installments thereafter.
Guardant Health director Steve E. Krognes reported the vesting and conversion of restricted stock units into common shares. On August 9, 2022 he received a restricted stock unit award that began vesting June 30, 2023, with 25% vesting then and the remaining 75% vesting in equal monthly installments over three years. On February 28, 2026, 154 restricted stock units vested and were converted at no cost into 154 shares of Guardant Health common stock. After these transactions, he directly held 618 restricted stock units and 19,053 shares of common stock.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units on February 21, 2026. These units, granted on November 8, 2024, convert into common stock at no cost as part of a four-year equity award vesting schedule.
Guardant Health director Manuel Hidalgo Medina reported acquiring shares through equity awards. On the vesting of a restricted stock unit grant on July 17, 2024, 232 restricted stock units converted into 232 shares of common stock at a price of $0.00 per share, reflecting an exercise or conversion of a derivative security rather than an open-market purchase. After these transactions, he directly holds 6,729 restricted stock units and 1,493 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported a routine equity compensation transaction. On February 15, 2026, he exercised or converted 250 Restricted Stock Units at $0 into 250 shares of Guardant Health common stock.
Following this derivative conversion, Musa directly holds 8,493 shares of common stock and 3,248 Restricted Stock Units. The RSUs were part of an award granted on March 6, 2023 that vests over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years.
Guardant Health director Steve Krognes reported a routine equity compensation event. On January 31, 2026, 154 Restricted Stock Units vested at an exercise price of $0, resulting in the acquisition of 154 shares of common stock. Following this transaction, he directly holds 18,899 shares of common stock and 772 Restricted Stock Units.
The vested RSUs come from an award granted on August 9, 2022, which vested 25% of the shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments over the three years after June 30, 2023.
Guardant Health Chief People Officer Terilyn J. Monroe reported multiple open-market sales of company stock. On January 21, 2026, she sold 1,703 shares of Guardant Health common stock at a weighted average price of $112.3418 per share, 3,619 shares at a weighted average price of $113.4793 per share, and 3,249 shares at a weighted average price of $115.6978 per share. Each sale was executed in multiple transactions within disclosed price ranges. After these sales, Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.
Guardant Health director Roberto Mignone reported a routine vesting of equity awards. On 01/21/2026, 264 Restricted Stock Units converted into 264 shares of Guardant Health common stock at an exercise price of $0 per share, increasing his directly held common stock to 3,959 shares. The related RSU award, granted on November 8, 2024, vests over four years: 25% of the shares vested on the one-year anniversary of 10/21/2024, and the remaining 75% vests in equal monthly installments over the following three years. After this vesting event, Mignone directly holds 8,712 RSUs in addition to his common shares.
Guardant Health director Manuel Hidalgo Medina reported a routine equity award vesting. On January 17, 2026, 232 Restricted Stock Units converted at an exercise price of $0 into 232 shares of common stock. After this transaction, he beneficially owned 1,261 shares of common stock directly and 6,961 Restricted Stock Units.
The Restricted Stock Units were granted on July 17, 2024 and vest over four years. 25% of the award vested on the one-year anniversary of that grant date, and the remaining 75% vests in equal monthly installments over the following three years.
Guardant Health director Musa Tariq reported the vesting and conversion of 250 restricted stock units into 250 shares of common stock at a price of $0 per share on January 15, 2026. Following this transaction, he directly owns 8,243 shares of Guardant Health common stock and 3,498 restricted stock units. The RSUs were granted on March 6, 2023 and vest over four years: 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health reported that Chief People Officer Terilyn J. Monroe had 17,379 Restricted Stock Units settle into 17,379 shares of Common Stock on January 15, 2026. Of these, 8,808 shares were retained by the company at $111.98 per share to satisfy tax withholding obligations, and she now holds 29,561 shares of Common Stock directly. The underlying RSU award was granted on February 26, 2024 and vests 33% on the one-year anniversary of January 15, 2024, with the remaining 67% vesting annually over the following two-year period.
Guardant Health’s Chief People Officer, Terilyn J. Monroe, reported selling common stock in three transactions on January 7, 2026. She sold 6,311 shares at a weighted average price of $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share. After these sales, she held 20,990 shares of Guardant Health common stock directly. The prices reported are weighted averages for multiple trades within disclosed price ranges.
Guardant Health, Inc. director reports RSU vesting and share acquisition. On 12/17/2025, reporting person Manuel Hidalgo Medina acquired 232 shares of Guardant Health common stock at a price of $0 through the settlement of previously granted restricted stock units, reported with transaction code M.
The restricted stock units were granted on July 17, 2024 and vest over four years, with 25% of the shares vesting on the one-year anniversary of that date and the remaining 75% vesting monthly over the following three years. After this transaction, the reporting person beneficially owns 1,029 shares of common stock directly and 7,193 restricted stock units.
Guardant Health, Inc. director Musa Tariq disclosed a small sale of company stock. On 12/17/2025, the reporting person sold 116 shares of Guardant Health common stock at a price of $101.46 per share. After this transaction, the director beneficially owned 7,993 shares of Guardant Health common stock, held in direct ownership. This filing is a routine insider ownership update and does not describe any additional transactions or derivative securities.
Guardant Health, Inc. director reports routine vesting of restricted stock units. On 12/15/2025, a reporting person who serves as a director of Guardant Health, Inc. (ticker GH) acquired 250 shares of common stock at a price of $0 through the vesting and settlement of previously granted restricted stock units. After this transaction, the director beneficially owned 8,109 shares of common stock directly and 3,748 restricted stock units that remain outstanding.
The restricted stock units were originally granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting in equal monthly installments over the following three-year period.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity compensation activity on December 15, 2025. 1,020 Restricted Stock Units converted into common stock at $0 per share, and 535 common shares were withheld by the company to meet tax withholding obligations at $102.67 per share, as explained in a footnote. After these transactions he directly holds 43,657 shares of Guardant Health common stock.
Guardant Health, Inc. (GH) disclosed an insider equity transaction by its Chief Information Officer, Kumud Kalia. On 12/15/2025, 637 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units. On the same date, 323 shares were disposed of at $102.67 per share, with the company retaining these shares to satisfy tax withholding obligations related to the vesting. After these transactions, the reporting person beneficially owned 22,679 shares of common stock directly, along with 1,275 restricted stock units that remain outstanding and subject to future vesting.
Guardant Health, Inc. reported an insider stock transaction by its Chief Commercial Officer. On December 15, 2025, the officer acquired 1,402 shares of common stock at $0 when a portion of a restricted stock unit (RSU) award vested. On the same date, 594 shares were withheld and disposed of at $102.67 per share to cover tax withholding obligations, as explained in the footnotes.
After these transactions, the officer directly owned 26,795 shares of Guardant Health common stock. The RSU award was originally granted on June 9, 2023; 33% vested on June 15, 2024, and the remaining 67% is scheduled to vest in equal quarterly installments over the following two years. Following the reported transaction, 2,804 restricted stock units remained beneficially owned.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported open-market sales of company stock. On 12/15/2025, he sold 83,945 shares of common stock at a weighted average price of $103.8012 per share, and an additional 6,620 shares at a weighted average price of $104.0224 per share. Both transactions are coded as sales. Following these trades, he beneficially owns 2,047,143 shares of Guardant Health common stock directly. The prices reflect multiple individual transactions within narrow price ranges, and detailed trade breakdowns are available upon request from the company or the reporting person.
Guardant Health, Inc. reported an insider equity transaction by its Chief Medical Officer, Craig Eagle. On 12/15/2025, 1,402 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of previously granted restricted stock units. On the same date, 711 shares were disposed of at $102.67 per share, retained by the company to cover tax withholding obligations related to this vesting.
Following these transactions, Craig Eagle beneficially owned 45,007 shares of Guardant Health common stock directly, and held 2,804 restricted stock units as derivative securities. The underlying restricted stock unit award was granted on June 9, 2023 and vests over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. (GH) Chief Technology Officer Darya Chudova sold 5,451 shares of common stock on 12/15/2025 at a weighted average price of $104.0418 per share. The sale was executed through multiple transactions at prices ranging from $104.0401 to $104.0900. Following this transaction, Chudova beneficially owns 7,012 shares of Guardant Health common stock in direct ownership.
Guardant Health, Inc.'s Chief Financial Officer, Michael Brian Bell, reported equity transactions involving restricted stock units and common stock. On 12/15/2025, 1,233 and 2,039 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common shares. On the same date, 1,659 shares of common stock were withheld and disposed of at $102.67 per share to satisfy tax withholding obligations related to the vesting, with the filing stating that the amount retained was not in excess of the tax liability. After these transactions, he directly beneficially owned 29,665 shares of common stock and held 4,078 restricted stock units that continue to vest over multi‑year schedules.
Guardant Health, Inc. reported insider equity transactions by its Chief Technology Officer, Darya Chudova, on Form 4. On 12/08/2025, 68,144 shares of common stock were transferred at no cost from her direct ownership to the Chudova Family Trust, changing the form of ownership from direct to indirect. The filing also shows two open-market sales of Guardant Health common stock on the same date: 9,271 shares sold at a weighted average price of $106.0029 per share and 13,664 shares sold at a weighted average price of $105.0371 per share, executed in multiple transactions within narrow price ranges.
After these transactions, Chudova reported beneficial ownership of 12,463 shares held directly and 54,480 shares held indirectly through the Chudova Family Trust. The disclosure notes that 488 of the shares in Table I were previously acquired under Guardant Health's Employee Stock Purchase Plan.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported a series of open-market sales of the company’s common stock on December 5, 2025. The Form 4 shows multiple sale transactions at weighted average prices including $101.4027, $102.0946, $103.2528, $103.9717, $105.9863 and $106.7081 per share, with each line representing shares sold across narrower intraday price ranges from $100.710 up to $106.990 per share. Each transaction is coded as a sale and reported as directly held. Following these sales, Freeman’s directly owned position in Guardant Health common stock is disclosed as 25,987 shares.
Guardant Health (GH) director Roberto A. Mignone reported an equity transaction involving restricted stock units and common stock. On 11/21/2025, 264 restricted stock units were converted into 264 shares of common stock at an exercise price of $0, reported under transaction code M.
Following this transaction, Mignone beneficially owned 3,431 shares of Guardant Health common stock directly and 9,240 restricted stock units. The RSU award was granted on November 8, 2024 and vests over four years: 25% of the shares vested on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director reports small stock sale
A director of Guardant Health, Inc., identified in the signature as Musa Tariq, reported selling 116 shares of the company’s common stock on 11/19/2025. The sale, coded as an "S" transaction, was executed at a price of $96.25 per share. After this transaction, the reporting person beneficially owns 7,859 shares of Guardant Health common stock, held in direct ownership.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported an equity award vesting and share issuance. On 11/17/2025, 232 restricted stock units converted into 232 shares of common stock at an exercise price of $0, increasing his directly held common stock to 1,047 shares.
The transaction reflects ongoing vesting from a restricted stock unit grant awarded on July 17, 2024. That grant vests over four years, with 25% of the shares vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting in equal monthly installments over the following three years. After this conversion, he continues to hold 7,425 restricted stock units directly.
Guardant Health, Inc. (GH) director Musa Tariq reported a routine equity transaction involving company stock. On 11/15/2025, 250 shares of Common Stock were acquired at a price of $0, following the vesting and settlement of a previously granted restricted stock unit award. After this transaction, Tariq beneficially owned 7,975 shares of Common Stock directly and held 3,998 restricted stock units directly.
The restricted stock units were granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health (GH) reported insider activity by director Manuel Hidalgo Medina. On 11/07/2025, he exercised 1,000 stock options at $32.55 and sold 1,500 shares in two trades at $95.1651 and $95.2301. Following these transactions, he held 815 shares directly.
The exercised option was granted on July 17, 2024 and expires on July 17, 2034. Per the award’s terms, 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years. After these transactions, he reported 16,029 derivative securities (stock options) beneficially owned.
Guardant Health (GH) reported an insider transaction by its Chief Legal Officer. On 11/07/2025, the reporting person sold 8,996 shares of common stock at a price of $96.25 per share. Following the sale, the filing shows 43,172 shares beneficially owned, held directly.
Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025. A restricted stock unit vested and settled into 154 shares of common stock at a stated price of $0 (transaction code M). Following the transaction, he directly beneficially owned 18,436 shares of common stock and held 1,235 RSUs as derivative securities.
The RSU grant was made on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal monthly installments over the next three years. The filing was made by one reporting person in his capacity as a Director.